COMPANY

Forward Therapeutics

Keywords: autoimmune diseases small molecule Psoriatic Arthritis

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · $50M · announced Oct 31, 2023 Company release ↗
Source quote
- Oct 31, 2023 · Company release ↗
  “Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Forward Therapeutics”

Raises announced in these releases: $50M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Oct 31, 2023 Raise Series A · $50M source ↗
2026-12 Trial start 2: Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis source ↗

2027-10 (ESTIMATED) · 2 · Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis · NCT07869134

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07869134	Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis	2	Not yet recruiting	2026-12	2027-10 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04